| Literature DB >> 32058995 |
Jieping Qiu1, Mengyu Sun1, Yaoqun Wang1, Bo Chen2.
Abstract
BACKGROUND Gastric adenocarcinoma accounts for 95% of all gastric malignant tumors. The purpose of this research was to identify differentially expressed genes (DEGs) of gastric adenocarcinoma by use of bioinformatics methods. MATERIAL AND METHODS The gene microarray datasets of GSE103236, GSE79973, and GSE29998 were imported from the GEO database, containing 70 gastric adenocarcinoma samples and 68 matched normal samples. Gene ontology (GO) and KEGG analysis were applied to screened DEGs; Cytoscape software was used for constructing protein-protein interaction (PPI) networks and to perform module analysis of the DEGs. UALCAN was used for prognostic analysis. RESULTS We identified 2909 upregulated DEGs (uDEGs) and 7106 downregulated DEGs (dDEGs) of gastric adenocarcinoma. The GO analysis showed uDEGs were enriched in skeletal system development, cell adhesion, and biological adhesion. KEGG pathway analysis showed uDEGs were enriched in ECM-receptor interaction, focal adhesion, and Cytokine-cytokine receptor interaction. The top 10 hub genes - COL1A1, COL3A1, COL1A2, BGN, COL5A2, THBS2, TIMP1, SPP1, PDGFRB, and COL4A1 - were distinguished from the PPI network. These 10 hub genes were shown to be significantly upregulated in gastric adenocarcinoma tissues in GEPIA. Prognostic analysis of the 10 hub genes via UALCAN showed that the upregulated expression of COL3A1, COL1A2, BGN, and THBS2 significantly reduced the survival time of gastric adenocarcinoma patients. Module analysis revealed that gastric adenocarcinoma was related to 2 pathways: including focal adhesion signaling and ECM-receptor interaction. CONCLUSIONS This research distinguished hub genes and relevant signal pathways, which contributes to our understanding of the molecular mechanisms, and could be used as diagnostic indicators and therapeutic biomarkers for gastric adenocarcinoma.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32058995 PMCID: PMC7034404 DOI: 10.12659/MSM.920261
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Volcano plot of all significant DEGs. Volcano plot of all significant DEGs, including a total of 2909 uDEGs and 7106 dDEGs. Red color means uDEGs, green color represents dDEGs, and blue color represents genes that are not significantly different in expression. The criterion: |foldchange|>1, p<0.05 is determined as the cutoff value.
Figure 2(A, B) Venn diagram of all screened DEGs. Venn diagram shows: uDEGs shared by GSE103236, GSE79973, and GSE29998 microarrays. A total of 92 uDEGs and 158 dDEGs were identified in the intersections.
DEGs in gastric adenocarcinoma shared in 3 microarrays.
| DEGS | Total | Elements |
|---|---|---|
| uDEGs | 92 | IGF2BP3, CDC25B, C5AR1, ZMYND15, COL1A1, GDPD5, ANLN, CHRNA5, FNDC1, COL18A1, PRRX1, PDGFRB, COL5A2, KIF4A, THY1, ASCL2, ANTXR1, SPP1, WNT5A, OLR1, MSR1, MELK, CDH11, TIMP1, BGN, COL8A1, TEAD4, ECT2, MMP11, KRT80, DDX31, FSCN1, SRPX2, WNT2, LRP8, CEMIP, BMP1, DIO2, ARPC1B, MFAP2, WISP1, VMO1, COL4A1, SLC1A3, SULF1, CLDN1, COL11A1, TREM1, COL1A2, APOC1, COL12A1, ESM1, ARHGAP11A, PLAU, RFC3, TGM2, OSMR, FOXC1, CHEK1, TNFRSF11B, VSNL1, IGFBP7, CST1, RCC2, LEF1, IL13RA2, LZTS1, SPHK1, KIF2C, AGPAT4, BUB1, TNFRSF12A, TROAP, ANGPT2, COL3A1, TMEM158, SERPINH1, FAP, INHBA, CDCA3, SLC5A6, CKAP2, THBS2, OLFML2B, S100A10, COL6A3, CSF2RA, HSD11B1, PMEPA1, CTHRC1, GAD1, NCAPG |
| dDEGs | 158 | EPB41L4B, COL4A5, ZNF385B, NRG4, IRX3, KLF4, NDRG2, IGFBP2, SLC9A2, SCNN1B, ESRRB, HTR4, F13A1, CNTD1, ADHFE1, CELA3B, OSBPL7, ADGRG2, MYOC, GIF, GPER1, HBB, GNG7, COL4A6, ERO1B, SOSTDC1, SBSPON, TMED6, ARHGAP24, CKMT2, KCNJ16, SLC26A7, ADAMTSL1, SYT4, PTGER3, ATP4A, DNASE1L3, CKB, MAL, AQP4, ESRRG, STOX2, CPA2, OXCT1, ABCA8, TTLL7, AXDND1, FXYD4, PER3, SHMT1, ETNPPL, DPT, PACRG, CAPN13, SLC5A5, FGA, NTN1, LGI1, ATP4B, EPM2A, SLC2A4, ADH1A, KLF15, SCUBE2, GPX3, KCNMB2, MAMDC2, SELENBP1, GPAT3, CLIC6, HAPLN1, TRIM50, B3GAT1, MS4A2, BHMT, GHRL, PNOC, GPRC5C, KCNJ13, DGKD, BMP6, GC, ALDH6A1, PDGFD, HTR1E, KIT, ADH1C, TOX, GCNT2, SST, PLCXD3, XYLT2, SLC6A16, CWH43, PDK4, GFRA2, GPR155, GREM2, NR3C2, PLA2G1B, MUC6, LINGO2, RNASE1, MYZAP, GUCA1C, AKR1C1, ACACB, PNPLA7, FXYD1, BAALC, PPP2R3A, BMP5, CKM, FBXL13, COBLL1, RGMB, FBP2, FAM150B, HIF3A, GSTA4, FGG, CHGA, RAB26, CAPN9, MT1M, SGSM1, ASPA, SCGN, SULT2A1, GAMT, CDHR3, CCKBR, ADRB2, GRIA3, SCGB2A1, SLC7A8, DUOX1, SORCS1, ARHGEF37, SCARA5, PACSIN1, LIFR, FNDC5, GLUL, CHIA, METTL7A, FAM189A2, SSTR1, PAIP2B, ACER2, ADH1B, MYRIP, KCNE2, PPP1R3C, TCEA3, PDE8B, SIGLEC11, KBTBD12 |
Figure 3Gene ontology analysis of DEGs related to gastric adenocarcinoma. The x-axis stands for the number of DEGs, and the vertical axis stands for GO terms, (A) The top 10 enriched biological processes (BP), cellular component (CC), and molecular function (MF) of 92 uDEGs. (B) The top 10 enriched BP, CC, and MF for 158 dDEGs.
Gene ontology analysis of DEGs related to gastric adenocarcinoma.
| Expression | Category | Term | Count | % | P value | FDR |
|---|---|---|---|---|---|---|
| Upregulated | GOTERM_BP_FAT | GO: 0001501~skeletal system development | 19 | 3.140495868 | 6.25E-17 | 1.67E-13 |
| GOTERM_BP_FAT | GO: 0007155~cell adhesion | 20 | 3.305785124 | 4.39E-12 | 6.55E-09 | |
| GOTERM_BP_FAT | GO: 0022610~biological adhesion | 20 | 3.305785124 | 4.50E-12 | 6.72E-09 | |
| GOTERM_BP_FAT | GO: 0030199~collagen fibril organization | 8 | 1.32231405 | 1.19E-11 | 1.78E-08 | |
| GOTERM_BP_FAT | GO: 0030198~extracellular matrix organization | 8 | 1.32231405 | 1.30E-07 | 1.95E-04 | |
| GOTERM_BP_FAT | GO: 0001503~ossification | 8 | 1.32231405 | 2.60E-07 | 3.89E-04 | |
| GOTERM_BP_FAT | GO: 0060348~bone development | 8 | 1.32231405 | 4.12E-07 | 6.16E-04 | |
| GOTERM_BP_FAT | GO: 0043062~extracellular structure organization | 8 | 1.32231405 | 2.75E-06 | 0.0041046 | |
| GOTERM_BP_FAT | GO: 0032963~collagen metabolic process | 5 | 0.826446281 | 3.71E-06 | 0.005542186 | |
| GOTERM_BP_FAT | GO: 0043588~skin development | 5 | 0.826446281 | 4.29E-06 | 0.006410681 | |
| GOTERM_CC_FAT | GO: 0005578~proteinaceous extracellular matrix | 25 | 4.132231405 | 1.86E-24 | 2.10E-21 | |
| GOTERM_CC_FAT | GO: 0031012~extracellular matrix | 25 | 4.132231405 | 1.14E-23 | 1.28E-20 | |
| GOTERM_CC_FAT | GO: 0005576~extracellular region | 40 | 6.611570248 | 6.86E-20 | 7.75E-17 | |
| GOTERM_CC_FAT | GO: 0044421~extracellular region part | 30 | 4.958677686 | 8.27E-19 | 9.34E-16 | |
| GOTERM_CC_FAT | GO: 0044420~extracellular matrix part | 14 | 2.314049587 | 1.64E-15 | 1.88E-12 | |
| GOTERM_CC_FAT | GO: 0005581~collagen | 9 | 1.487603306 | 1.49E-12 | 1.68E-09 | |
| GOTERM_CC_FAT | GO: 0005583~fibrillar collagen | 5 | 0.826446281 | 1.48E-07 | 1.67E-04 | |
| GOTERM_CC_FAT | GO: 0005604~basement membrane | 6 | 0.991735537 | 2.04E-05 | 0.023013251 | |
| GOTERM_CC_FAT | GO: 0031093~platelet alpha granule lumen | 5 | 0.826446281 | 2.76E-05 | 0.031185256 | |
| GOTERM_CC_FAT | GO: 0060205~cytoplasmic membrane-bounded vesicle lumen | 5 | 0.826446281 | 3.67E-05 | 0.041403378 | |
| GOTERM_MF_FAT | GO: 0005201~extracellular matrix structural constituent | 11 | 1.818181818 | 5.06E-13 | 5.90E-10 | |
| GOTERM_MF_FAT | GO: 0005198~structural molecule activity | 14 | 2.314049587 | 3.15E-07 | 3.67E-04 | |
| GOTERM_MF_FAT | GO: 0005518~collagen binding | 5 | 0.826446281 | 8.88E-06 | 0.010355681 | |
| GOTERM_MF_FAT | GO: 0005539~glycosaminoglycan binding | 7 | 1.157024793 | 1.19E-05 | 0.013923194 | |
| GOTERM_MF_FAT | GO: 0001871~pattern binding | 7 | 1.157024793 | 2.05E-05 | 0.023961179 | |
| GOTERM_MF_FAT | GO: 0030247~polysaccharide binding | 7 | 1.157024793 | 2.05E-05 | 0.023961179 | |
| GOTERM_MF_FAT | GO: 0008201~heparin binding | 6 | 0.991735537 | 3.72E-05 | 0.043401787 | |
| GOTERM_MF_FAT | GO: 0050840~extracellular matrix binding | 4 | 0.661157025 | 1.30E-04 | 0.151895387 | |
| GOTERM_MF_FAT | GO: 0005509~calcium ion binding | 12 | 1.983471074 | 4.20E-04 | 0.488103889 | |
| GOTERM_MF_FAT | GO: 0008237~metallopeptidase activity | 6 | 0.991735537 | 5.52E-04 | 0.641829759 | |
| Downregulated | GOTERM_BP_FAT | GO: 0007586~digestion | 12 | 1.038062284 | 7.45E-12 | 1.09E-08 |
| GOTERM_BP_FAT | GO: 0055114~oxidation reduction | 15 | 1.297577855 | 3.07E-05 | 0.045029161 | |
| GOTERM_BP_FAT | GO: 0006081~cellular aldehyde metabolic process | 4 | 0.346020761 | 6.53E-04 | 0.952399247 | |
| GOTERM_BP_FAT | GO: 0030001~metal ion transport | 10 | 0.865051903 | 0.00213818 | 3.08666015 | |
| GOTERM_BP_FAT | GO: 0006812~cation transport | 10 | 0.865051903 | 0.006666616 | 9.333089916 | |
| GOTERM_BP_FAT | GO: 0006811~ion transport | 12 | 1.038062284 | 0.007065784 | 9.865306976 | |
| GOTERM_BP_FAT | GO: 0046903~secretion | 7 | 0.605536332 | 0.010249221 | 14.00683938 | |
| GOTERM_BP_FAT | GO: 0015672~monovalent inorganic cation transport | 7 | 0.605536332 | 0.01337189 | 17.89646714 | |
| GOTERM_BP_FAT | GO: 0006813~potassium ion transport | 5 | 0.432525952 | 0.016821807 | 22.00279704 | |
| GOTERM_BP_FAT | GO: 0022600~digestive system process | 3 | 0.259515571 | 0.018374485 | 23.78773935 | |
| GOTERM_CC_FAT | GO: 0005576~extracellular region | 31 | 2.6816609 | 1.26E-05 | 0.014253173 | |
| GOTERM_CC_FAT | GO: 0045177~apical part of cell | 7 | 0.605536332 | 0.001371031 | 1.545706714 | |
| GOTERM_CC_FAT | GO: 0016324~apical plasma membrane | 6 | 0.519031142 | 0.002113034 | 2.373127171 | |
| GOTERM_CC_FAT | GO: 0005624~membrane fraction | 11 | 0.951557093 | 0.047644803 | 42.55171216 | |
| GOTERM_MF_FAT | GO: 0031420~alkali metal ion binding | 7 | 0.605536332 | 0.004013875 | 5.198242704 | |
| GOTERM_MF_FAT | GO: 0004033~aldo-keto reductase activity | 3 | 0.259515571 | 0.004305787 | 5.566366984 | |
| GOTERM_MF_FAT | GO: 0004198~calcium-dependent cysteine-type endopeptidase activity | 3 | 0.259515571 | 0.004899806 | 6.31139254 | |
| GOTERM_MF_FAT | GO: 0008289~lipid binding | 9 | 0.778546713 | 0.009796998 | 12.2496158 | |
| GOTERM_MF_FAT | GO: 0016620~oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor | 3 | 0.259515571 | 0.010025001 | 12.51741656 | |
| GOTERM_MF_FAT | GO: 0030955~potassium ion binding | 5 | 0.432525952 | 0.010277041 | 12.81257072 | |
| GOTERM_MF_FAT | GO: 0008233~peptidase activity | 10 | 0.865051903 | 0.013517076 | 16.52574449 | |
| GOTERM_MF_FAT | GO: 0015267~channel activity | 8 | 0.692041522 | 0.019316845 | 22.80964632 | |
| GOTERM_MF_FAT | GO: 0022803~passive transmembrane transporter activity | 8 | 0.692041522 | 0.01954695 | 23.04969236 | |
| GOTERM_MF_FAT | GO: 0008900~hydrogen: potassium-exchanging ATPase activity | 2 | 0.173010381 | 0.019742308 | 23.25294859 |
KEGG pathway analysis of DEGs associated with gastric adenocarcinoma.
| Expression | Term | Count | % | P value | FDR |
|---|---|---|---|---|---|
| Upregulated | hsa04512: ECM-receptor interaction | 11 | 1.818181818 | 2.66E-13 | 2.14E-10 |
| hsa04510: Focal adhesion | 11 | 1.818181818 | 1.80E-09 | 1.44E-06 | |
| hsa04350: TGF-beta signaling pathway | 4 | 0.661157025 | 0.005149174 | 4.056689024 | |
| Downregulated | hsa00982: Drug metabolism | 8 | 0.692041522 | 1.46E-07 | 1.41E-04 |
| hsa00830: Retinol metabolism | 7 | 0.605536332 | 1.38E-06 | 0.001338048 | |
| hsa00980: Metabolism of xenobiotics by cytochrome P450 | 7 | 0.605536332 | 2.60E-06 | 0.002518197 | |
| hsa00010: Glycolysis/Gluconeogenesis | 4 | 0.346020761 | 0.007818033 | 7.311759835 | |
| hsa00591: Linoleic acid metabolism | 3 | 0.259515571 | 0.015552893 | 14.070282 | |
| hsa00350: Tyrosine metabolism | 3 | 0.259515571 | 0.036348334 | 30.10544025 |
Figure 4PPI network construction, module analysis, and pathway enrichment analysis. Protein-protein interaction network for products of DEGs. A total of 143 nodes and 419 interaction associations were identified. (A) The nodes mean proteins; the edges mean the interactions of proteins; green circles meant dDEGs and orange circles meant uDEGs. (B) Module analysis based on Cytoscape software. (C) KEGG pathway enrichment analysis of DEGs in the module.
Connectivity and regulation of the top 10 hub genes.
| Gene symbol | Gene title | Connectivity | Regulation |
|---|---|---|---|
| COL1A1 | Collagen type I alpha 1 chain | 34 | Up |
| COL3A1 | Collagen type III alpha 1 chain | 30 | Up |
| COL1A2 | Collagen type I alpha 2 chain | 29 | Up |
| BGN | Biglycan | 29 | Up |
| COL5A2 | Collagen type V alpha 2 chain | 23 | Up |
| THBS2 | Thrombospondin 2 | 23 | Up |
| TIMP1 | TIMP metallopeptidase inhibitor 1 | 21 | Up |
| SPP1 | Secreted phosphoprotein 1 | 20 | Up |
| PDGFRB | Platelet-derived growth factor receptor beta | 20 | Up |
| COL4A1 | Collagen type IV alpha 1 chain | 19 | Up |
Figure 5Validation of the gene expression levels of COL1A1, COL3A1, COL1A2, BGN, COL5A2, THBS2, TIMP1, SPP1, PDGFRB, and COL4A1 between GAC and normal gastric tissues in the GEPIA database. They are significantly upregulated in GAC compared with normal tissues (P<0.01). The red * represents P<0.01.
Figure 6UALCAN overall survival analysis plot of the top 10 hub genes expressed in gastric adenocarcinoma patient samples and 4 DEGs among the top 10 hub genes that are significantly related to the survival of gastric adenocarcinoma patients (P<0.05). (A) COL3A1; (B) COL1A2; (C) BGN; (D) THBS2.